Taysha Gene Therapies, Inc.
TSHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $297 | $313 | $117 | $139 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $4 | $4 | $3 |
| Total Curr. Assets | $300 | $316 | $121 | $142 |
| Property Plant & Equip (Net) | $14 | $15 | $15 | $16 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $2 | $2 | $2 |
| Total NC Assets | $17 | $17 | $18 | $18 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $317 | $333 | $138 | $160 |
| Liabilities | – | – | – | – |
| Payables | $5 | $8 | $4 | $4 |
| Short-Term Debt | $2 | $2 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $5 | $7 | $10 |
| Other Curr. Liab. | $22 | $10 | $9 | $11 |
| Total Curr. Liab. | $29 | $25 | $23 | $26 |
| LT Debt | $67 | $58 | $60 | $61 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $1 | $1 | $1 |
| Total NC Liab. | $69 | $59 | $61 | $63 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $18 | $19 | $19 | $19 |
| Total Liabilities | $98 | $85 | $83 | $89 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$683 | -$651 | -$624 | -$602 |
| AOCI | -$1 | -$1 | -$2 | -$4 |
| Other Equity | $904 | $900 | $681 | $678 |
| Total Equity | $219 | $249 | $55 | $72 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $317 | $333 | $138 | $160 |
| Net Debt | -$228 | -$253 | -$55 | -$76 |